Unknown

Dataset Information

0

Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial.


ABSTRACT: Lanthanum carbonate (FOSRENOL, Shire Pharmaceuticals) is an effective noncalcium, nonresin phosphate binder for the control of hyperphosphatemia in chronic kidney disease (CKD) stage 5 patients undergoing dialysis.A Phase 2, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of lanthanum carbonate in CKD stage 3 and 4 patients. Of 281 patients screened, 121 were randomized (2:1) to lanthanum carbonate or placebo (80 versus 41). The modified intent-to-treat population included 90 patients (56 versus 34); 71 (43 versus 28) completed the study. After run-in, when any current phosphate binders were discontinued and dietary counseling reinforced, patients with serum phosphorus >4.6 mg/dl received lanthanum carbonate (titrated up to 3000 mg/d) or matching placebo for 8 wk.At the end of treatment, 25 (44.6%) versus nine (26.5%) patients had serum phosphorus < or =4.6 mg/dl (difference 18.1%, P = 0.12) in the lanthanum carbonate and placebo groups, respectively. Statistically significant differences were observed between groups in change from baseline to end of treatment for serum phosphorus (P = 0.02), intact parathyroid hormone (P = 0.02), and urinary phosphorus excretion (P = 0.04). The safety profile and tolerability of lanthanum carbonate were similar to that of placebo.Because <1% of phosphorus is in the extracellular fluid, serum measurements may not accurately reflect total body burden in patients with CKD stages 3 and 4. However, lanthanum carbonate is an effective phosphate binder in this patient population, with a safety profile and tolerability similar to that of placebo.

SUBMITTER: Sprague SM 

PROVIDER: S-EPMC2615694 | biostudies-literature | 2009 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial.

Sprague Stuart M SM   Abboud Hanna H   Qiu Ping P   Dauphin Matthew M   Zhang Pinggao P   Finn William W  

Clinical journal of the American Society of Nephrology : CJASN 20081203 1


<h4>Background and objectives</h4>Lanthanum carbonate (FOSRENOL, Shire Pharmaceuticals) is an effective noncalcium, nonresin phosphate binder for the control of hyperphosphatemia in chronic kidney disease (CKD) stage 5 patients undergoing dialysis.<h4>Design, setting, participants and measurements</h4>A Phase 2, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of lanthanum carbonate in CKD stage 3 and 4 patients. Of 281 patients screened, 121 were randomized  ...[more]

Similar Datasets

| S-EPMC6035139 | biostudies-literature
| S-EPMC5263092 | biostudies-literature
| S-EPMC9923701 | biostudies-literature
| S-EPMC9012343 | biostudies-literature
| S-EPMC3570485 | biostudies-literature
| S-EPMC8491672 | biostudies-literature
| S-EPMC6551774 | biostudies-literature
| S-EPMC6251566 | biostudies-other
| S-EPMC8132143 | biostudies-literature
| S-EPMC5718266 | biostudies-literature